ArticleAmerican journal of translational research2026
Norcantharidin induces apoptosis in hepatocellular carcinoma MHCC97-H cells in association with altered NF-κB/IκBα signaling dynamics and JNK activation.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Norcantharidin (NCTD), a demethylated derivative of cantharidin, has antitumor activity against multiple cancer types; however, its effects on the NF-κB/JNK signaling axis in hepatocellular carcinoma (HCC) remain incompletely defined. MHCC97-H HCC cells were treated with NCTD at 5, 20, and 40 μg/mL (approximately 29.7, 118.9, and 237.9 μM), alone or in combination with pyrrolidine dithiocarbamate (PDTC, 50 μM), a compound with reported NF-κB inhibitory and antioxidant properties. NCTD suppressed cell viability in a dose- and time-dependent manner, with 48-h inhibition rates of 24.3%, 51.9%, and 72.1% at the three concentrations. Based on the available MTS data, the estimated NCTD IC50 was > 40 μg/mL at 24 h and approximately 19.0 μg/mL at 48 h. Flow cytometry showed corresponding apoptosis rates of 13.3%, 36.8%, and 43.2%, which increased to 50.2% after PDTC co-treatment. Western blotting showed reduced nuclear NF-κB p65 signal and decreased cytoplasmic IκBα levels, together with increased phosphorylated JNK (p-JNK), while total JNK remained unchanged. RT-qPCR showed upregulation of pro-apoptotic Bax, downregulation of anti-apoptotic Bcl-2, and increased c-Jun, TNF-α, and IL-6 transcripts. NCTD further impaired colony formation, induced G0/G1 arrest, depolarized mitochondrial membrane potential, and increased reactive oxygen species. TCGA-LIHC bulk RNA-seq data were analyzed to provide clinical context. NF-κB pathway genes were differentially expressed in HCC, and enrichment analyses implicated NF-κB, apoptosis, TNF, and MAPK-related pathways. The NF-κB Core activity score showed no significant tumor-normal difference, but immune infiltration analysis revealed associations between NF-κB activity and the HCC immune microenvironment. These findings indicate that NCTD triggers mitochondrial apoptosis in MHCC97-H cells in association with reduced nuclear p65 signal, altered IκBα turnover, stress/inflammatory gene induction, and enhanced JNK activation, rather than demonstrating uniform blockade of the entire NF-κB pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.